References
1. Organization WH. Coronavirus disease 2019 (COVID-19): situation
report, 72. 2020.
2. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier
transmission of COVID-19. Jama. 2020;323(14):1406-1407.
3. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine
storm syndromes and immunosuppression. Lancet (London, England).2020;395(10229):1033.
4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of
coronavirus disease (COVID-19) outbreak. Journal of autoimmunity.2020:102433.
5. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of
bronchoalveolar lavage fluid and peripheral blood mononuclear cells in
COVID-19 patients. Emerging microbes & infections.2020;9(1):761-770.
6. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6,
surfactant protein-A, surfactant protein-D, and monocyte chemoattractant
protein-1 as serum markers for interstitial lung diseases.American journal of respiratory and critical care medicine.2002;165(3):378-381.
7. Li G, Siddiqui J, Hendry M, et al. Surfactant protein-A–deficient
mice display an exaggerated early inflammatory response to a β-resistant
strain of influenza A virus. American journal of respiratory cell
and molecular biology. 2002;26(3):277-282.
8. Yuen K-S, Ye Z-W, Fung S-Y, Chan C-P, Jin D-Y. SARS-CoV-2 and
COVID-19: The most important research questions. Cell &
bioscience. 2020;10(1):1-5.
9. Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: role
of chloroquine and anti-IL-6 monoclonal antibodies. International
journal of antimicrobial agents. 2020.
10. Cao Y-c, Deng Q-x, Dai S-x. Remdesivir for severe acute respiratory
syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.Travel Medicine and Infectious Disease. 2020:101647.
11. Channappanavar R, Perlman S. Pathogenic human coronavirus
infections: causes and consequences of cytokine storm and
immunopathology. Paper presented at: Seminars in immunopathology2017.
12. Russell B, Moss C, George G, et al. Associations between
immune-suppressive and stimulating drugs and novel COVID-19—a
systematic review of current evidence. ecancermedicalscience.2020;14.
13. Henderson LA, Canna SW, Schulert GS, et al. On the alert for
cytokine storm: Immunopathology in COVID‐19. Arthritis &
Rheumatology. 2020.
14. McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in
COVID-19 pneumonia related macrophage activation syndrome.Autoimmunity reviews. 2020:102537.
15. Ye Q, Wang B, Mao J. The pathogenesis and treatment of theCytokine
Storm’in COVID-19. The Journal of infection. 2020.
16. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular
endothelialitis, thrombosis, and angiogenesis in Covid-19. New
England Journal of Medicine. 2020.
17. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6
(IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine
release syndrome (CRS)? Journal of Autoimmunity. 2020:102452.
18. Greene K, Ye S, Mason R, Parsons P. Serum surfactant protein-A
levels predict development of ARDS in at-risk patients. Chest.1999;116:90S-91S.
19. Ballard PL, Nogee LM, Beers MF, et al. Partial deficiency of
surfactant protein B in an infant with chronic lung disease.Pediatrics. 1995;96(6):1046-1052.
20. Mason RJ, Greene K, Voelker DR. Surfactant protein A and surfactant
protein D in health and disease. American Journal of
Physiology-Lung Cellular and Molecular Physiology. 1998;275(1):L1-L13.
21. Hartshorn KL. Role of surfactant protein A and D (SP-A and SP-D) in
human antiviral host defense. Front Biosci (Schol Ed).2010;2(1):527-546.
Table 1. Comparison of laboratory parameters of COVID-19
patients at admission and on day 5 of treatment